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OBJECTIVE — To investigate the prevalence of maturity-onset diabetes of the young
(MODY) in Italian children with incidental hyperglycemia.
RESEARCH DESIGN AND METHODS — Among 748 subjects age 1–18 years with
incidental hyperglycemia, minimal diagnostic criteria for MODY were met by 172 families.
Mutational analyses of the glucokinase (GCK) and hepatocyte nuclear factor 1 (HNF1) genes
were performed.
RESULTS — We identiﬁed 85 GCK gene mutations in 109 probands and 10 HNF1 muta-
tionsin12probands.InGCKpatients,themedianneonatalweightandageattheﬁrstevaluation
were lower than those found in patients with HNF1A mutations. Median fasting plasma glucose
and impaired fasting glucose/impaired glucose tolerance frequency after oral glucose tolerance
testingwerehigherinGCKpatients,whoalsoshowedalowerfrequencyofdiabetesthanHNF1A
patients.
CONCLUSIONS — GCK mutations are the prevailing cause of MODY (63.4%) when the
index case is recruited in Italian children with incidental hyperglycemia.
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B
etween1992–1999,theItalianSoci-
ety of Pediatric Endocrinology and
Diabetology (ISPED) Study Group
on childhood pre-diabetes recruited 748
individuals with incidental hyperglyce-
mia to be screened for markers of type 1
diabetes (1,2). Among autoantibody-
negative subjects, a signiﬁcant number
(23%) met the criteria for clinical diag-
nosis of maturity-onset diabetes of the
young (MODY), i.e., two or three consec-
utive generations with hyperglycemia di-
agnosed before age 25 years (3,4).
Alterations in at least six different genes
cause MODY (3), with mutations of the
glucokinase (GCK) and hepatocyte nu-
clear factor 1 (HNF1) genes account-
ing for up to 85% of MODY in Europe.
Defects of other MODY genes are quite
rare (3). The aim of this study was to
screen for GCK and HNF1 genes in 172
Italian children with incidental hypergly-
cemia and clinical diagnosis of MODY.
RESEARCH DESIGN AND
METHODS— Islet cell antibodies, in-
sulin autoantibodies, IA-2 antigens, and
GAD antibodies were assayed in 748 sub-
jects (480 males, age 1–18 years) referred
to the 35 participating centers for inci-
dentally discovered hyperglycemia. Each
centerprovidedareportonthosesubjects
with incidental hyperglycemia who satis-
ﬁed the diagnostic criteria of MODY. In-
formed consent for genetic analysis was
obtained from all families following ap-
proval from local ethical committees. The
percentile of birth weight after correction
for gestational age, sex, and BMI was cal-
culated using standard charts (5,6). Mu-
tation carriers were classiﬁed according
theirfastingplasmaglucose(FPG)follow-
ing the latest recommendations of the
American Diabetes Association. When
available, oral glucose tolerance test
(OGTT) data were analyzed.
Mutation screening
Ampliﬁcation of GCK and HNF1 genes
was accomplished by PCR, and various
rapidscreeningmethodsofPCRproducts
were used (e.g., single-strand conforma-
tional polymorphism or denaturing gra-
dient gel electrophoresis). This was
followed by direct DNA sequencing of
samples different from reference PCR.
Statistical analysis
Proportions were compared between
MODY groups using the Fisher’s exact
test, and means and medians were com-
pared using the Student’s t test and the
Mann-WhitneyUtest,respectively,orthe
Kruskal-Wallis test. Logistic models were
ﬁtted to compute the probability of diag-
nosis of HNF1 and GCK, and their 95%
CIs, according to FPG and OGTT. Stata
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RESULTS
GCK gene screening
A total of 213 subjects from 172 families
metMODYdiagnosticcriteria,and85dif-
ferent GCK mutations were identiﬁed in
109 probands (109 of 172  63.4%); our
group has already reported about 75 of
theseprobands(4,7).Intheremaining34
families, we identiﬁed 14 novel and 20
previously described (8,9) mutations.
Eleven of the novel mutations were mis-
sensemutationsandthreewerepointmu-
tations, which, although they do not
predict amino acid changes, still could
have a pathogenic potential (CONCLUSIONS
and online appendix Table A1, available
at http://care.diabetesjournals.org/cgi/
content/full/dc08-2018/DC1). Each mu-
tation was conﬁrmed in the affected
parentandavailablefamilymemberswith
the exception of three subjects in which
themutationarosedenovo.Allmutations
were not found in 200 normal chromo-
somes. Of note, only 25% of family trees
of GCK probands met the stringent crite-
ria for MODY (i.e., three known consec-
utive generations with diabetes or related
conditions).
HNF1A gene screening
We detected 10 different HNF1A muta-
tions (one novel: p.Arg363Cys) in 12 un-
related patients (12 of 172  6.9%) (10).
In a single patient mutation, p.Pro291fs
(c.872duplC) arose de novo. Ninety per-
cent of HNF1A-MODY families showed
three consecutive generations with diabe-
tes or related conditions.
MODY with unknown genetic origin
Of172probands,51(29.6%)werenegative
for GCK and HNF1A genes. The genetic de-
fectwasthereforeunknownintheseMODY
probands.
Clinical and metabolic parameters
Age at ﬁrst evaluation and birth weight
were lower in GCK patients than in
HNF1A patients. GCK patients had a
lower frequency of normal FPG and a
higher frequency of impaired fasting glu-
cose than HNF1A patients. At OGTT,
GCK patients showed a higher frequency
of impaired glucose tolerance and a lower
frequency of diabetes than HNF1A pa-
tients (Table 1).
CONCLUSIONS— We conﬁrmed
that in the largest Italian case series of pe-
diatric patients clinically deﬁned as
MODY, mutations of GCK are very fre-
quent (63.4%), while HNF1A are rela-
tively rare (6.9%). It is possible, however,
that we have slightly underestimated the
latter because the methodologies utilized
in our investigation cannot detect large
deletions. Thus, approximately one-third
of our families may carry either a muta-
tioninanyoftherareMODYgenes(3)or,
morelikely,inalocusyettobefound.We
considered pathogenetically two varia-
tions of GCK gene at the end of exons 1a
(c.45G3A) and 4 (c.483G3A) that
changed guanine to adenine in the third
base of the codon (AAG3AAA) (online
appendix Table A1). Because both AAG
and AAA encode the amino acid lysine,
this variation is usually regarded as “si-
lent.” However, both mutations change
the exonic consensus guanine at the 5
exon/intron boundary, a location that in
other genes has been demonstrated to de-
termine exon skipping or other defects
(11). We also considered pathogeneti-
cally an intronic change outside the
splice-siteconsensussequence(c.1019
5G3A) but substituting a highly con-
served guanine in the 5 consensus splice
site (12). All three mutations were found
along three consecutive generations of af-
fected family members and were not de-
tected in 200 normal chromosomes.
Though we did not provide in vitro evi-
dence that these mutations have deleteri-
ous consequences, it is likely that they
cause GK haplo-insufﬁciency (11,12).
In this study, a high prevalence of
GCKmutationshasbeenfound,similarto
previous investigations conducted in the
pediatric setting (3,13). In contrast,
HNF1A mutations were rarely detected,
probably because of the reduced pen-
etranceofmutationsofHNF1Ainsubjects
under 18 years of age (14). However, true
differences in the prevalence of MODY
genes between populations cannot be ex-
cluded at this time, as suggested by the
low prevalence of HNF1A mutations
(16%) in Italian families with MODY re-
cruited in the adult diabetes clinic (15)
(online appendix Table A2). In conclu-
sion, our study indicates that autoanti-
body-negative children with (stable)
incidental hyperglycemia and a parent
with the same condition are good candi-
Table 1—Clinical and metabolic analyses in carriers of GCK, HNF1A, and MODY of unknown type (UT) mutations
GCK HNF1A UT P
Birth weight (g) 3,050 (2,790–3,370) 3,570 (2,975–4,205) 3,075 (2,950–3,520) 0.100
Age at 1st visit (years) 7.6  3.6* 13.2  6.2† 10.3  3.4† 0.001
BMI at 1st visit 17 (14–24) 21 (13–25) 17 (16–20) 0.929
FPG (mmol/l) 6.3 (5.8–6.7) 6.1 (5.5–6.6) 6.0 (5.6–6.4) 0.099
OGTT  120 (mmol/l) 8.37  1.77‡ 10.23  4.5§ 9.45  2.52‡ 0.102
FPG and OGTT outcome 0.001
NFG and NGT 3 (3) 4 (31) 1 (4)
IFG or IGT 100 (83) 2 (15) 17 (71)
DM/DM 17 (14) 7 (54) 6 (25)
FPIR (pmol/l) 438 (306–624) 300 (240–432) 570 (294–876) 0.084
FPIR percentiles 0.073
25th 70 (71) 7 (100) 12 (52)
25th–75th 25 (26) 0 8 (35)
	75th 3 (3) 0 3 (13)
Dataaremedian(25th–75thpercentile),meansSD,andn(%).*Vs.HNF1A,UT;†vs.GCK;‡vs.HNF1A;§vs.GCK,UT.Forposthoccomparisons:P0.017(after
Bonferroni correction) (GCK) vs. GCK;( HNF1A) vs. HNF1A and (X) vs. unknown. DM, diabetes mellitus; FPIR, ﬁrst-phase insulin response; NFG, normal fasting
glucose; NGT, normal glucose tolerance.
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